A protest over a draft decision not to recommend a new cystic fibrosis drug is due later. Campaigners keen to see Kalydeco introduced across Wales are aiming to make their voices heard outside a meeting of the All Wales Medicines Strategy Group at the Angel Hotel in Abergavenny.
The group will look at the recommendation and decide whether to approve it or not. The drug - which is already available in England, Scotland and Northern Ireland - is the first licensed drug that treats the G551D mutation - the fundamental defect in those with cystic fibrosis.
More top news
The tide is turning in favour of more unsettled weather over the next few days!
The world record attempt will raise money for the foundation set up in memory of the Olympic gold medallist, who died in May 2013.
In today's Newsweek, Carl talks about what the 'No' vote in the Scottish Referendum could mean for Wales and the impact of legal highs.